User Settings
Article10.1158/1538-7445.sabcs14-p4-11-04

Abstract P4-11-04: Intrinsic subtypes and BCL2 as predictive and prognostic biomarkers in the TACT2 trial (CRUK/05/019)

James P. Morden,Judith M. Bliss,Jane Bayani,Robert Laing,R. K. Agrawal,Jeremy Thomas+7 more-2015-05-01-Cancer Research
1

TL;DRAbstract

Abstract Introduction: TACT2, a multicentre randomized phase III trial in patients with node +ve or high risk node-ve invasive EBC with E-CMF as control tested two hypotheses in a 2x2 factorial design, presented results showing: i) no evidence of benefit from accelerated 2-weekly epirubicin (aE) compared to standard 3-weekly epirubicin (E) (Cameron 2012); and ii) capecitabine (X) gives equivalent efficacy but preferential side-effect profile to CMF (Canney 2014). Here we present prognostic and potential predictive value of translational biomarkers. We address two main hypotheses: i) aE is less effective in patients with luminal A than patients with other subtypes (Coates 2012) and ii) BCL2 is an independent prognosis marker (Callagy 2006). We also explore the relationship between CK5/6, EGFR and BCL2 and residual risk following chemotherapy. Methods: Tumour samples were collected prospectively from 3803 patients (86.6% of the 4391 TACT2 patients and 94.5% of those consenting). Tissue m

Chat with Paper

AI Agents for this Paper

Abstract Introduction: TACT2, a multicentre randomized phase III trial in patients with node +ve or high risk node-ve invasive EBC with E-CMF as control tested two hypotheses in a 2x2 factorial design, presented results showing: i) no evidence of benefit from accelerated 2-weekly epirubicin (aE) compared to standard 3-weekly epirubicin (E) (Cameron 2012); and ii) capecitabine (X) gives equivalent efficacy but preferential side-effect profile to CMF (Canney 2014). Here we present prognostic and potential predictive value of translational biomarkers. We address two main hypotheses: i) aE is less effective in patients with luminal A than patients with other subtypes (Coates 2012) and ii) BCL2 is an independent prognosis marker (Callagy 2006). We also explore the relationship between CK5/6, EGFR and BCL2 and residual risk following chemotherapy. Methods: Tumour samples were collected prospectively from 3803 patients (86.6% of the 4391 TACT2 patients and 94.5% of those consenting). Tissue m

Keywords

EpirubicinCapecitabineMedicineInternal medicineOncologyTissue microarrayPredictive markerImmunohistochemistry

Chat

Click to start Chat